Life-sciences M&A activity in the Gulf is set to surge as governments boost healthtech and biologics investments. Furthermore, life-sciences M&A is reshaping the regional healthcare landscape, creating opportunities for local and international companies.
Gulf governments are actively strengthening biotechnology and healthcare manufacturing. Moreover, they are forging long-term partnerships and encouraging acquisitions to secure strategic capabilities.
Grand View Research recently released a study showing a turning point in Middle East mergers and acquisitions. The report indicates that the Gulf Cooperation Council prioritises technology transfer, contract development, and upstream sourcing of health inputs. In addition, these initiatives directly support Saudi Vision 2030 and the UAE Life Sciences Strategy.
These strategies aim to improve supply chains for biosimilars, cell-based therapies, and advanced medical treatments. Consequently, localisation helps the region build an ecosystem that serves local needs and scales globally.
The report notes that the Middle East healthcare Contract Development & Manufacturing Organisation market reached $6.27 billion in 2024. Analysts project it will rise to $11.91 billion by 2033, reflecting a compound annual growth rate of 7.5%. Similarly, the bioprocessing segment could more than double from $1.16 billion to $2.44 billion during the same period.
Swayam Dash, Managing Director of Grand View Research, said, “Dubai and the broader GCC sit at the crossroads of science, capital, and policy. That convergence is driving acquisitions and joint ventures.”
Investors are focusing on cell therapy raw materials, which represent one of the fastest-growing markets. Furthermore, the sector is projected to expand from $39.2 million in 2024 to $169.8 million by 2033, offering substantial opportunities for innovation and growth.
Moreover, the Gulf’s localisation initiatives attract regional and international investment. Companies actively pursue mergers and partnerships to strengthen advanced therapy ecosystems and enhance competitiveness in global markets.
Experts expect these initiatives to transform the Gulf into a hub for life sciences innovation. Therefore, strategic acquisitions and collaborations will support research, manufacturing, and global expansion.
Overall, life-sciences M&A in the Gulf is entering a dynamic phase. Additionally, governments and private investors are driving growth, with projected healthtech and biologics investments reaching Dh44 billion by 2033.
